Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas | Zendy

Andrew Lin | Zendy; Jingxia Liu | Zendy; J.G. Evans | Zendy; Eric C. Leuthardt | Zendy; Keith M. Rich | Zendy; Ralph G. Dacey | Zendy; Joshua L. Dowling | Zendy; Albert H. Kim | Zendy; Gregory J. Zipfel | Zendy; Robert L. Grubb | Zendy; Jiayi Huang | Zendy; Clifford G. Robinson | Zendy; Joseph R. Simpson | Zendy; Gerald P. Linette | Zendy; Michael R. Chicoine | Zendy; David Tran | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas

Author(s) -

Andrew Lin,

Jingxia Liu,

J.G. Evans,

Eric C. Leuthardt,

Keith M. Rich,

Ralph G. Dacey,

Joshua L. Dowling,

Albert H. Kim,

Gregory J. Zipfel,

Robert L. Grubb,

Jiayi Huang,

Clifford G. Robinson,

Joseph R. Simpson,

Gerald P. Linette,

Michael R. Chicoine,

David Tran

Publication year - 2013

Publication title -

neuro-oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.005

H-Index - 125

eISSN - 1523-5866

pISSN - 1522-8517

DOI - 10.1093/neuonc/not142

Subject(s) - oligodendroglioma , medicine , confidence interval , odds ratio , oncology , glioma , multivariate analysis , retrospective cohort study , chemoradiotherapy , oligodendroglial tumor , gastroenterology , cancer , astrocytoma , cancer research

Pseudoprogression (PsP) occurs at a higher rate in glioblastoma multiforme with a methylated MGMT promoter-a subset with increased sensitivity to chemoradiotherapy and better overall prognosis. In oligodendroglioma (OG) and oligoastrocytoma (OA), presence of 1p/19q codeletions is highly predictive of response to treatment and is often associated with the methylated MGMT promoter; hence, this study queries whether the presence of 1p/19q codeletions in OG/OA correlates with a higher rate of PsP following therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research